Table 3.

Selected Clinical Trials investigating tumor vaccination in myeloid malignancies.

Trial	Treatment	Diagnosis	Outcome Measures	Status, Response, Comments
NCT03566446 (Phase I)	CALRLong36 peptide (Ex 9 mut) vaccine	CALR-mutant MPN (ET, PMF, MPN unclassifiable)	Primary: AE; Secondary: Immune response (T-cell cytokine release), mutation status, ORR	Active; No trial results posted yet; CALRLong36 peptide did show prompt responses in vitro
NCT01266083 (Phase II)	WT1 peptide vaccine	AML, ALL; patients being in CR; patients with WT1+ disease	Primary: AE, OS; Secondary: DFS, Immunol. ogic response, effects on MRD, OS	Completed; Vaccine was well tolerated; AEs: injection site reaction, fatigue, skin induration; vaccine-stimulated specific immune response
NCT02750995 (Phase I)	NPMW-peptide vaccine (against long peptide sequences from NY-ESO-1, PRAME, MAGE-A3, WT-1); Azacitidine	High-risk MDS, AML (<30% blasts)	Primary: AE; Secondary: specific T-cell reactivity, ORR	Recruiting
NCT03358719 (Phase I)	DEC-205/NY-ESO-1 Fusion Protein CDX-1401; Decitabine; Nivolumab	AML (<30% blasts), MDS, high-risk MDS, CMML, refractory anemia	Primary: AE; Secondary: immune profile, PB and BM response, CRR, PRR	Active; final data collection for primary outcome measure

AE: adverse events; AML: Acute myeloid leukemia; ALL: Acute lymphoblastic leukemia; BM: bone marrow; CMML: chronic myelomonocytic leukemia; CR: complete remission; CRR: complete response rate; DFS: disease-free survival; MDS: Myelodysplastic Syndrome; MPN: myeloproliferative neoplasm; ORR: overall response rate; OS: overall survival; PB: peripheral blood; PMF: primary myelofibrosis; PRR: partial remission rate.